All Publications
Quantitative measurement of alterations in DNA damage repair (DDR) pathways using single cell network profiling (SCNP).
J Transl Med 2014;12:184.
High-dimensional analysis of the aging immune system: Verification of age-associated differences in immune signaling responses in healthy donors.
J Transl Med 2014;12:178.
Profiling signaling pathways in CLL PD-1+ CD8 T cells identifies features of “pseudo-exhaustion”.
Presented at: Keystone Symposia: Immune Evolution in Cancer (X2). March 9–14, 2014; Whistler, British Columbia, CA.
Systems biology analysis of immune signaling in peripheral blood mononuclear cells (PBMC) of melanoma patients receiving ipilimumab; basis for response biomarker identification.
Presented at: 3rd Annual Melanoma Bridge; December 5–8, 2013; Naples, IT.
Single cell network profiling (SCNP): technology and its application to the development of cancer immunotherapy.
Presented at: 13th Euroconference on Clinical Cell Analysis; November 12–4, 2013; Luxembourg, LU.
Systems biology analysis of immune signaling in peripheral blood mononuclear cells (PBMC) of melanoma patients receiving ipilimumab; basis for response biomarker identification.
Presented at: 28th Annual Meeting of the Society for Immunotherapy of Cancer; November 8–10, 2013; National Harbor, MD.
Prediction of TNF inhibitor response in Rheumatoid Arthritis patients using Single Cell Network Profiling of intracellular immune signaling.
Presented at: Annual Meeting of the American College of Rhematology; October 25–30, 2013; San Diego, CA.
Novel biomarkers from peripheral blood mononuclear cells indicate disease activity in Rheumatoid Arthritis patients.
Presented at: Annual Meeting of the American College of Rhematology; October 25–30, 2013; San Diego, CA.
Application of SCNP technology to autoimmunity for both disease characterization and prediction of response to therapy.
Presented at: 28th Annual Meeting of the International Clinical Cytometry Society; October 11–5, 2013; Fort Lauderdale, FL.
Validation of cell-based fluorescence assays: Practice guidelines from the ICSH and ICCS - part III - analytical issues.
Cytometry Part B 2013; 84(5).
Age-related changes of healthy bone marrow cell signaling in response to growth factors provide insight into low risk MDS.
Cytometry Part B 2013; doi: 10.1002/cytob.21125.
Comparison of functional immune signaling profiles in peripheral blood mononuclear cells (PBMC) from rheumatoid arthritis (RA) patients versus healthy donors (HD) using Single Cell Network Profiling (SCNP).
Presented at: 15th International Congress of Immunology; August 22–7, 2013; Milan, IT.
Functional proteomic interrogation of immune cell crosstalk and the effects of cytokine-targeted inhibitors using Single Cell Network Profiling (SCNP).
Presented at: 15th International Congress of Immunology; August 22–7, 2013; Milan, IT.
Vaccine hyporesponse in healthy elderly subjects is associated with a decrease in B cell IFN-α responses: Data from functional proteomic analysis using single cell network profiling.
Presented at: 3rd International Conference on Vaccines & Vaccination; July 29–31, 2013; Las Vegas, NV.
Single cell network profliling (SCNP) analysis reveals dysfunctional signaling within the Th17 axis in chronic lymphocytic leukemia (CLL).
Presented at: 18th Congress of the European Hematology Association; June 13–6, 2013; Stockholm, SE.
Deregulation of stem cell factor (SCF)-AKT-S6 pathway in diagnostic AML samples is associated with disease-free survival: results of a verification study.
Presented at: 18th Congress of the European Hematology Association; June 13–6, 2013; Stockholm, SE.
Development and validation of a single-cell network profiling assay-based classifier to predict response to induction therapy in paediatric patients with de novo acute myeloid leukaemia: a report from the Children's Oncology Group.
British Journal of Haematology 2013; 10.1111/bjh.12370: ePub ahead of print.
Functional characterization of KIT and FcεR1 receptor mutations in Mast Cell Leukemia using Single Cell Network Profiling (SCNP).
Presented at: 104th Annual Meeting of the American Association for Cancer Research; April 6–10, 2013; Washington, DC.
Quantitative measurements of EGFR pathway signaling and modulation in pleural effusion samples from non-small cell lung cancer (NSCLC) patients using single cell network profiling (SCNP).
Presented at: 104th Annual Meeting of the American Association for Cancer Research; April 6–10, 2013; Washington, DC.
Fighting Cancer with Python.
Presented at: PyCon 2013; March 13–21, 2013; Santa Clara, CA.
Functional pathway analysis using SCNP of FLT3 receptor pathway deregulation in AML provides prognostic information independent from mutational status.
PLOS One 2013;8(2):e56714.
AKT signaling as a novel factor associated with in-vitro resistance of human AML to gemtuzumab ozogamicin.
PLoS ONE 2013;8(1):e53518.
Single Cell Network Profiling Assay in Bladder Cancer.
Cytometry Part A 2013; 83(1).
Assessing germline Homologous Recombination pathway deficiency in BRCA1 mutation carriers using Single Cell Network Profiling.
Presented at: 35th Annual Meeting of the San Antonia Breast Cancer Symposium (SABCS); December 4–8, 2012; San Antonio, TX.
Single cell network profiling (SCNP) identifies altered signaling between patient risk groups in B-cell chronic lymphocytic leukemia (B-CLL).
Presented at: 54th Annual Meeting of the American Society of Hematology; December 8–11, 2012; Atlanta, GA.
Single cell network profiling (SCNP) of early-stage chronic lymphocytic leukemia (CLL): Association with p53, IGHV mutational status and time to first treatment (TTFT).
Presented at: 54th Annual Meeting of the American Society of Hematology; December 8–11, 2012; Atlanta, GA.
Single cell network profiling (SCNP)-based classifier to predict response to induction therapy in elderly patients with acute myeloid leukemia (AML): Validation in two independent sample sets from ECOG and SWOG trials.
Presented at: 54th Annual Meeting of the American Society of Hematology; December 8–11, 2012; Atlanta, GA.
Association between B-cell receptor responsiveness and disease progression in B-cell chronic lymphocytic leukemia: results from single cell network profiling studies.
Haematologica 2012;97. [ePub ahead of print]
CTLA-4 defines distinct T cell signaling populations in healthy donors and metastatic melanoma patients.
Presented at: 27th Annual Meeting of the Society for Immunotherapy of Cancer; October 24–8, 2012; North Bethesda, MD.
Functional pathway analysis using single cell network profiling (SCNP) shows prognostic value in patients with B-cell chronic lymphocytic leukemia (B-CLL): results of training & test studies.
Presented at: 2nd World Congress of Controversies in Hematology; September 6–8, 2012; Barcelona, SP.
Assessing signaling pathways associated with in vitro resistance to cytotoxic agents in AML.
Leuk Res 2012;36:900-904.
Racial differences in B cell receptor signaling pathway activation.
J Transl Med 2012;10:113.
Single Cell Network Profiling (SCNP) assay application to bladder cancer samples: identifying rare EGF responsive epithelial cancer cells sensitive to PI3K inhibition from bladder cancer washings.
Presented at: Annual Meeting of the American Urological Association; May 19–23, 2012; Atlanta, GA.
Single cell network profiling (SCNP) assay allows for the identification of heterogeneity in the activation of multiple signaling pathways in distinct human B cell subsets.
Presented at: 99th Annual Meeting of the American Association of Immunology; May 4–8, 2012; Boston, MA
Leveling the playing field: bringing development of biomarkers and molecular diagnostics up to the standards for drug development.
Clin Cancer Res 2012;18:1515-1523.
Single-cell network profiling of peripheral blood mononuclear cells from healthy donors reveals age- and race-associated differences in immune signaling pathway activation.
J Immunol; Prepublished online 13 January 2012; doi:10.4049/jimmunol.1102514.
Functional pathway analysis in acute myeloid leukemia using single cell network profiling assay: effect of specimen source (bone marrow or peripheral blood) on assay readouts.
Cytometry Part B 2012;82B:158-172.
Making personalized cancer medicine a reality: challenges and opportunities in the development of biomarkers and companion diagnostics.
Clin Cancer Res 2012;18:619-624.
Single cell network profiling (SCNP)-based classifier to predict response to induction therapy in pediatric patients with de novo acute myeloid leukemia (AML): validation study results.
Presented at: 53rd Annual Meeting of the American Society of Hematology; December 10–13, 2011; San Diego, CA.
BCR responsiveness is associated with time to first treatment (TTFT) in B-cell chronic lymphocytic leukemia (B-CLL): results from a single cell network profiling (SCNP) verification study.
Presented at: 53rd Annual Meeting of the American Society of Hematology; December 10–13, 2011; San Diego, CA.
Single cell network profiling (SCNP) functionally characterizes FLT3 pathway deregulation in non-M3 acute myeloid leukemia (AML) and provides prognostic value independent from mutational status.
Presented at: 53rd Annual Meeting of the American Society of Hematology; December 10–13, 2011; San Diego, CA.
Single cell network profiling (SCNP) reveals age- and disease-based heterogeneity in healthy individuals and in patients with low risk (LR) myelodysplastic syndrome (MDS).
Presented at: 53rd Annual Meeting of the American Society of Hematology; December 10–13, 2011; San Diego, CA.
Single cell network profiling (SCNP) reveals race-associated differences in B cell receptor signaling pathway activation.
Presented at: 53rd Annual Meeting of the American Society of Hematology; December 10–13, 2011; San Diego, CA.
Impact of time from blood draw to peripheral blood mononuclear cell (PBMC) processing and cryopreservation as functional pathway activity measured by single cell network profiling (SCNP) assays.
Presented at: 53rd Annual Meeting of the American Society of Hematology; December 10–13, 2011; San Diego, CA.
Single cell network profiling (SCNP) assay application to bladder cancer (BC) samples: Identifying rare epidermal growth factor (EGF) responsive epithelial cancer cells sensitive to PI3K inhibition from bladder washings.
Presented at: AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International Conference; November 12–16, 2011; San Francisco, CA.
Assessing specific biological mechanisms of drug resistance in adult and pediatric AML.
Presented at: AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International Conference; November 12–16, 2011; San Francisco, CA.
Integrating in vitro signaling and drug response data from single cell network profiling (SCNP) to inform on individual's AML biology.
Presented at: AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International Conference; November 12–16, 2011; San Francisco, CA.
Association of reactive oxygen species-mediated signal transduction with in vitro apoptosis sensitivity in chronic lymphocytic leukemia B cells.
PLoS One 2011;6(10):e24592. doi:10.1371/journal.pone.0024592.
Using Single-cell Network Profiling (SCNP) signatures to predict response to induction therapy and relapse risk in paediatric patients with acute myeloid leukemia (AML).
Presented at: The European Multidisciplinary Cancer Congress; September 23–7, 2011; Stockholm, Sweden.
Poly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality.
Mol Med 2011;17:854-862.
Mapping immune cell signaling network responses using single cell network profiling in peripheral blood mononuclear cells from healthy donors: defining “normal”.
Presented at: Annual meeting of the Clinical Immunology Society; May 19–22, 2011; Chicago, IL.
Single-cell network profiling (SCNP) to evaluate the proteomic profiles associated with ON 01910.Na treatment of MDS patients (pts).
Presented at: 102nd Annual Meeting of the American Association for Cancer Research; April 2–6, 2011; Orlando, FL.
Signaling changes in the stem cell factor–AKT-S6 pathway in diagnostic AML samples.
Blood Cancer Journal. (2011) 1, e3; doi:10.1038/bcj.2010.2.
Beyond sequencing: new diagnostic tests turn to pathways.
JNCI J Natl Cancer Inst. 2011;103(4):290-2.
Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much?
Clin Cancer Res 2010;16:5972-5980.
Single cell network profiling (SCNP) signatures predict response to induction therapy and relapse risk in pediatric patients with acute myeloid leukemia: Children's Oncology Group (COG) study POG-9421.
Presented at: 52nd Annual Meeting of the American Society of Hematology; December 4–7, 2010; Orlando, FL.
Single cell network profiling (SCNP) assay reveals B cell receptor signaling heterogeneity in the context of ZAP-70 expression in patients with chronic lymphocytic leukemia (CLL).
Presented at: 52nd Annual Meeting of the American Society of Hematology; December 4–7, 2010; Orlando, FL.
Characterization of FLT3 pathway deregulation by single cell network profiling (SCNP) stratifies AML patients beyond molecular profiling.
Presented at: 52nd Annual Meeting of the American Society of Hematology; December 4–7, 2010; Orlando, FL.
Single cell network profiling as a platform to reveal leukemia-specific signaling signatures and sensitivity to kinase inhibitor therapies.
Presented at: 52nd Annual Meeting of the American Society of Hematology; December 4–7, 2010; Orlando, FL.
Single-cell network profiling (SCNP) signatures independently predict response to induction therapy in older patients with acute myeloid leukemia (AML).
Presented at: 52nd Annual Meeting of the American Society of Hematology; December 4–7, 2010; Orlando, FL.
Specimen source (BM or PB) does not affect proteomic signaling in patients with AML and circulating blasts.
Presented at: 52nd Annual Meeting of the American Society of Hematology; December 4–7, 2010; Orlando, FL.
Cellular and intracellular network characterization of cytokine JAK/STAT signaling in whole blood across multiple healthy individuals: defining “normal”.
Presented at: 52nd Annual Meeting of the American Society of Hematology; December 4–7, 2010; Orlando, FL.
Sample cryopreservation does not affect functional read outs in SCNP assays: implications for biomarker development.
Presented at: 52nd Annual Meeting of the American Society of Hematology; December 4–7, 2010; Orlando, FL.
Single cell network profiling (SCNP) of IFN-α signaling pathways in peripheral blood mononuclear cells from healthy donors: implications for disease characterization, treatment selection, and drug discovery.
Presented at: 52nd Annual Meeting of the American Society of Hematology; December 4–7, 2010; Orlando, FL.
Single-Cell Network Profiling (SCNP) by flow cytometry in autoimmune disease.
Autoimmunity. 2010;43:550-9.
Functional characterization of FLT3 receptor signaling deregulation in acute myeloid leukemia by single cell network profiling (SCNP).
Plos One. 2010;5(10):e13543.
Single cell network profiling by flow cytometry as a platform to reveal pathway signatures and drug response profiles for use in personalized medicine.
Presented at: 4th Annual AACR International Conference on Molecular Diagnositcs in Cancer Therapeutic Development; September 27–30, 2010; Denver, CO.
Modulated multiparametric phosphoflow cytometry in hematological malignancies: technology and clinical applications.
Best Pract Res Clin Haematol. 2010;23(3):319-31.
Immune system networks and their reorganization in rheumatoid arthritis.
Presented at: 14th International Congress of Immunology; August 22–7, 2010; Kobe, JP.
Distinct patterns of DNA damage response and apoptosis correlate with JAK/STAT and PI3Kinase response profiles in human acute myelogenous leukemia.
Plos One. 2010;5(8):e12405.
Dynamic single cell network profiles in AML are associated with patient response to standard induction therapy.
Clin Cancer Res. 2010;16:3721-33.
Single cell network profiling (SCNP) offers a novel approach to identify at diagnosis AML chemotherapy resistant cell phenotypes.
Presented at: 15th Congress of the European Hematology Assocation; June 10–13, 2010; Barcelona, SP.
BCR signaling profiles associated with prognosis and progression in B-CLL.
Presented at: 15th Congress of the European Hematology Assocation; June 10–13, 2010; Barcelona, SP.
Biological characterization of AML at the single cell level based on response to DNA damaging agents.
Presented at: 15th Congress of the European Hematology Assocation; June 10–13, 2010; Barcelona, SP.
Dynamic single cell network profiles (SCNP) in AML are associated with patient response to standard induction therapy.
Presented at: 15th Congress of the European Hematology Assocation; June 10–13, 2010; Barcelona, SP.
Single Cell Network Profiling (SCNP): mapping drug and target interactions.
Assay Drug Dev Technol. 2010;8:321-43.
Informatics platform and workflows for robust high throughput single cell network profiling (SCNP).
Presented at: 25th Congress of the International Society for the Advancement of Cytometry; May 8–12, 2010; Seattle, WA.
A comparative analysis of quantitative techniques using flow and mass cytometric platforms.
Presented at: 25th Congress of the International Society for the Advancement of Cytometry; May 8–12, 2010; Seattle, WA.
Reproducibility of single cell network profiling using multiparameter flow cytometry.
Presented at: 25th Congress of the International Society for the Advancement of Cytometry; May 8–12, 2010; Seattle, WA.
Towards robust evaluation of gating in flow cytometry.
Presented at: 25th Congress of the International Society for the Advancement of Cytometry; May 8–12, 2010; Seattle, WA.
The revolution is here - are you ready?
EJHP Practice. 2010;16:12.
Identification of distinct apoptosis and myeloid signaling profiles within acute myeloid leukemia (AML) blast subpopulations.
Presented at: 101st Annual Meeting of the American Association for Cancer Research; April 17–21, 2010; Washington, DC.
Insights into acute myeloid leukemia via single cell network profiling.
CLi. 2010;34:12-5.
Classification of acute myeloid leukemia (AML) based on apoptosis and myeloid signaling networks.
Presented at: 51st Annual Meeting of the American Society of Hematology; December 5–8, 2009; New Orleans, LA.
Single cell network profiling (SCNP) to evaluate the mechanism of action of ON 01910.Na, a novel clinical trial stage compound.
Presented at: 51st Annual Meeting of the American Society of Hematology; December 5–8, 2009; New Orleans, LA.
Single cell network profiling as a tool to identify AML chemotherapy resistant cell phenotypes under in vivo therapeutic pressure.
Presented at: 51st Annual Meeting of the American Society of Hematology; December 5–8, 2009; New Orleans, LA.
Distinct signaling profiles of gemtuzumab ozogamicin responsiveness and refractoriness in acute myeloid leukemia.
Presented at: 51st Annual Meeting of the American Society of Hematology; December 5–8, 2009; New Orleans, LA.
Cost burden analysis of ineffective induction chemotherapy in elderly patients with AML.
Abstract presented at: 51st Annual Meeting of the American Society of Hematology; December 5–8, 2009; New Orleans, LA.
FLT3-ITD signaling profiles in AML samples harboring mutations.
Blood (ASH Annual Meeting Abstracts). 2009;114:Abstract 1588.
Quantitative assessment of myeloid nuclear differentiation antigen distinguishes myelodysplastic syndrome from normal bone marrow.
Presented at: 51st Annual Meeting of the American Society of Hematology; December 5–8, 2009; New Orleans, LA.
Single cell network profiles in non-M3 AML associated with patient response to standard induction therapy.
Presented at: 51st Annual Meeting of the American Society of Hematology; December 5–8, 2009; New Orleans, LA.
Single cell profiling of B cell receptor signaling and apoptosis networks in chronic lymphocytic leukemia: association with in vitro sensitivity to fludarabine monophosphate (F-ara-A).
Presented at: 51st Annual Meeting of the American Society of Hematology; December 5–8, 2009; New Orleans, LA.
Single cell network profiling (SCNP) by flow cytometry as a tool to measure potency and selectivity of JAK/STAT inhibitors in PBMC and whole blood discrete cell subsets.
Presented at: AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International Conference; October 19–23, 2009; Boston, MA.
Educating for personalized medicine: a perspective from oncology.
Clinical Pharmacology And Therapeutics. July 2009;86(1):23-25.
Patient-specific classifications of human malignant disease.
Curr Opin Mol Ther. 2009;11:252-9.
Distinct proteomic signaling networks stratify response to ara-C based induction therapy in patients with acute myeloid leukemia (AML).
Presented at: 50th Annual Meeting of the American Society of Hematology; December 6–9, 2008; San Francisco, CA.
High level phosphatase activity revealed in chronic lymphocytic leukemia cells that use mutated immunoglobulin heavy chain variable region genes and lack high-level expression of the zeta-associated protein 70 (ZAP-70).
Presented at: 49th Annual Meeting of the American Society of Hematology; December 8–11, 2007; Atlanta, GA.
What's wrong with drug screening today.
Nat Chem Biol. 2007;3:187-191.
Mapping normal and cancer cell signalling networks: towards single-cell proteomics.
Nature Rev Cancer. 2006;6:146-55.
Fluorescent cell barcoding in flow cytometry allows high-throughput drug screening and signaling profiling.
Nat Methods. 2006;3:361-36.
Single cell profiling of potentiated phospho-protein networks in cancer cells.
Cell. 2004;118:217-28.